
CLAIMS

1. A compound of **Formula (I)**:




(I)


or a pharmaceutically acceptable salt thereof,

wherein:

A	is a protein binder unit;
Z	is $\mathbf{Z^A}$ or $\mathbf{Z^B}$:



$\mathbf{Z^A}$



$\mathbf{Z^B}$

wherein:

------	represents a single covalent bond or a double covalent bond;
1 of $\mathbf{X^A}$, $\mathbf{X^B}$, $\mathbf{X^C}$ & $\mathbf{X^D}$	is C**Y**;
0, 1 or 2 of $\mathbf{X^A}$, $\mathbf{X^B}$, $\mathbf{X^C}$, $\mathbf{X^D}$, $\mathbf{X^E}$ & $\mathbf{X^F}$	is/are N where $\mathbf{X^E}$ & $\mathbf{X^F}$ are not both N, and are otherwise C;


and when **Z** is $\mathbf{Z^A}$:

2 of $\mathbf{X^G}$, $\mathbf{X^H}$ & $\mathbf{X^J}$	are independently selected from C and N; and
1 of $\mathbf{X^G}$, $\mathbf{X^H}$ & $\mathbf{X^J}$	is C, N, S or O;
	where at least one of $\mathbf{X^G}$, $\mathbf{X^H}$ & $\mathbf{X^J}$ is N, S or O; and
	where any one C of $\mathbf{X^G}$, $\mathbf{X^H}$ & $\mathbf{X^J}$ is optionally substituted by oxo, or when both of $\mathbf{X^G}$ & $\mathbf{X^J}$ are C, they both may be optionally substituted by oxo; and

and when **Z** is $\mathbf{Z^B}$

1 of $\mathbf{X^G}$, $\mathbf{X^H}$, $\mathbf{X^J}$ & $\mathbf{X^K}$	is N and are otherwise C; or alternatively
$\mathbf{X^G}$ & $\mathbf{X^K}$	are both N and $\mathbf{X^H}$ & $\mathbf{X^J}$ are both C;
Linker	is a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of

		attachment ‘a’ and ‘b’ (and where ‘b’ may involve two attachment points ‘b1’ and ‘b2’ in cases where there are two points of attachment to **Z** at the ‘b’ end of the **Linker**) and a minimum length of from 6 to 26 atoms between ‘a’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; wherein said **Linker** is attached either:
	once to **Z**:	at any available C or N atom of **Z**; or
	twice to **Z**:	at any two adjacent available C atom(s) and/or N atom(s) at $\mathbf{X^H}$, $\mathbf{X^G}$ & $\mathbf{X^J}$ (& $\mathbf{X^K}$ when present) such that a 5 to 7-membered ring is formed by the attachment of the **Linker** at the two adjacent atoms of **Z**;
	each $\mathbf{R^A}$	is a substituent on any available C or N atom of **Z** – in each case independently selected from $\mathbf{R^{A1}}$ optionally substituted by one or more $\mathbf{R^{A2}}$; where $\mathbf{R^A}$ is further selected from $\mathbf{R^{A2}}$ when $\mathbf{R^A}$ is a substituent on an available C atom of **Z**;
	each $\mathbf{R^{A1}}$	is independently C_{1-4}alkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, C_{1-3}alkoxyC_{1-3}alkyl, carboxyC_{1-3}alkyl, C_{5-7}carbocyclyl or a 4-6 membered heterocyclyl;
	each $\mathbf{R^{A2}}$	is independently selected from F, Cl, Br, CN, NH_2, C_{1-3}alkyl, O(C_{1-3}alkyl), NH(C_{1-3}alkyl) and N(C_{1-3}alkyl)$_2$; wherein said C_{1-3}alkyls are optionally substituted by one or more F;
	v	is 0, 1, 2 or 3;
	Y	is:



		wherein:
	$\mathbf{Y^A}$ & $\mathbf{Y^B}$	together represent CH-CH or C=C wherein $\mathbf{Y^A}$ & $\mathbf{Y^B}$ are each independently substituted by H, F, CN or Me.

2. The compound of **Formula (I)**, as claimed in claim 1, or a pharmaceutically acceptable salt thereof, wherein the framework of the **Linker** is a saturated or partially unsaturated framework.


3. The compound of **Formula (I)**, as claimed in claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein the framework of the **Linker** comprises C and H atoms and at least two heteroatoms selected from N & O.

4. The compound of **Formula (I)**, as claimed in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the framework of the **Linker** includes from 2 to 10 heteroatoms.

5. The compound of **Formula (I)**, as claimed in any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the total number of C and hetero atoms in the **Linker** framework is from 8 to 30.

6. The compound of **Formula (I)**, as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein **Y** and **Linker** are not attached at adjacent positions of **Z**.


7. A PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**:



(Ia)

or a pharmaceutically acceptable salt thereof,
wherein the values of **Z**, **Y**, $\mathbf{R^A}$ and **v** are as defined in claim 1.

8. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, as claimed in claim 7, or a pharmaceutically acceptable salt thereof, where said PROTAC compound contains a unit of **Formula (Ib)**:



(Ib)

wherein:


Q^C Ring is a 4-11 membered saturated heterocyclic group;

E is linked to an available C or available N atom of **Z**, where

when **E** is linked to an available C atom of **Z**, **E** is C or N, and

when **E** is linked to an available N atom of **Z**, **E** is C.

9. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, as claimed in claim 7, or a pharmaceutically acceptable salt thereof, where said PROTAC compound contains a unit of **Formula (Ic)**:



(Ic)

wherein **t** is 1 or 2.

10. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein 0 or 1 of X^A, X^B, X^C, X^D, X^E & X^F is N, and are otherwise C.

11. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein when **Z** is Z^A; X^G, X^H & X^J are collectively selected from (N, C, C), (O, N, C), (N, C, S), (N, N, N), (S, C, C), (N, N, C), (N, C, N), (O, C, C), (O, C, N), (C, N, C) and (N, N, C) respectively.

12. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein when **Z** is Z^A; the (X^G-X^H-X^J) group together is selected from (N-C=C), (N-C-C), (N=C-C), (O-N=C), (N=C-S), (N-N=N), (S-C=C), (N-N=C), (N-C=N), (O-C=C), (O-C=N), (O-C-N), (C-N-C) and (N-N-C).

13. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein **Z** is selected from indole, benzisoxazole, 1*H*-pyrrolo[2,3-*c*]pyridine, benzothiazole, 1*H*-pyrrolo[3,2-*b*]pyridine, indoline, benzotriazole, indazole, benzothiophene, 2*H*-indazole, benzimidazole, benzofuran, benzoxazole, 3*H*-1,3-benzoxazol-2-one, pyrazolo[1,5-*a*]pyridine, isoindolin-1-one, imidazo[1,2-*a*]pyridine, isoindoline, isoxazo[4,5-*b*]pyridine, furo[3,2-*b*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline.

14. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein **Z**, **Y**, $\mathbf{R^A}$ and **v** are collectively represented by any one or more of formulae 1 to 54 as shown in the description.


15. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein $\mathbf{R^A}$ is a substituent on any available C or N atom of **Z** – in each case independently selected from $C_{1\text{-}3}$alkyl, $N(C_{1\text{-}3}alkyl)_2$ and $C_{1\text{-}3}alkoxyC_{1\text{-}3}$alkyl and $\mathbf{R^A}$ is further selected from F, Cl, CN and $C_{1\text{-}3}$alkoxy when said $\mathbf{R^A}$ is a substituent on an available C of **Z**.

16. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein **Y** is selected from 6-fluoro-2,4-dioxohexahydropyrimidin-1-yl, 6-fluoro-2,4-dioxo-pyrimidin-1-yl, 2,4-dioxopyrimidin-1-yl, 6-methyl-2,4-dioxo-pyrimidin-1-yl and 2,6-dioxohexahydropyrimidin-1-yl.

17. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein **Y** is 2,6-dioxohexahydropyrimidin-1-yl.

18. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein **Z**, **Y**, $\mathbf{R^A}$ and **v** are collectively represented by any one or more of formulae 1 to 107 as shown in the description.

19. A compound of **Formula (II)**:



(II)

or a salt thereof, wherein:

$\mathbf{R^J}$ is H or a N-protecting group;

$\mathbf{Q^C}$ **Ring** is a 4-11 membered saturated heterocyclic group;

E is linked to an available C or available N atom of **Z**, where


when **E** is linked to an available C atom of **Z**, **E** is C or N, and

when **E** is linked to an available N atom of **Z**, E is C;

and the values of **Z**, **Y**, $\mathbf{R^A}$ and **v** are as defined in any preceding claim.

20. The compound of **Formula (II)** as claimed in claim 19, or a salt thereof, wherein the N-protecting group is *tert*-butoxycarbonyl.

21. A compound of **Formula (III)**:



(III)

or a salt thereof, wherein:

w is 1 or 2;

$\mathbf{R^H}$ is H or $C_{1\text{-}8}$hydrocarbyl;

and the values of **Z**, **Y**, $\mathbf{R^A}$ and **v** are as defined in any preceding claim and where the compound of **Formula (III)** is other than 3-[6-(2,4-dioxohexahydropyrimidin-1-yl)-2-oxo-1,3-benzoxazol-3-yl]-propanoic acid.

22. A pharmaceutical composition, which comprises a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, in association with a pharmaceutically acceptable excipient.

23. A pharmaceutical composition which comprises a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, in association with a pharmaceutically acceptable excipient.

24. A pharmaceutical composition, which comprises a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in the treatment of cancer.

25. A pharmaceutical composition, which comprises a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in the treatment of cancer.

26. A pharmaceutical composition, which comprises a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in the treatment of a solid tumour.

27. A pharmaceutical composition, which comprises a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in the treatment of a solid tumour.

28. A pharmaceutical composition, which comprises a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in the treatment of a BRD4-sensitive tumour type.

29. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use as a medicament.

30. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use as a medicament.

31. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in therapy.

32. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in therapy.

33. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in a method of treatment of the human or animal body by therapy.

34. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in a method of treatment of the human or animal body by therapy.

35. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18 for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

36. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

37. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18 for use in the production of a protein degrading effect in a warm-blooded animal such as man.

38. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in the production of a protein degrading effect in a warm-blooded animal such as man.

39. Use of a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for the manufacture of a medicament for the production of an anti-proliferative effect (for example, in a warm-blooded animal such as man).

40. Use of a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for the manufacture of a medicament for the production of an anti-proliferative effect in a warm-blooded animal such as man.

41. Use of a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for the manufacture of a medicament for the production of a protein degrading effect in a warm-blooded animal such as man.

42. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

43. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

44. Use of a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

45. Use of a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for the manufacture

of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

46. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in the prevention or treatment of cancer.

47. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in the prevention or treatment of cancer.

48. Use of a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for the manufacture of a medicament for the prevention or treatment of cancer.

49. Use of a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for the manufacture of a medicament for the prevention or treatment of cancer.

50. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in the prevention or treatment of solid tumour(s).

51. The PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for use in the prevention or treatment of solid tumour(s).

52. Use of a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for the manufacture of a medicament for the prevention or treatment of solid tumour(s).

53. Use of a PROTAC compound containing an E3 ubiquitin ligase binding unit of **Formula (Ia)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 7 to 18, for the manufacture of a medicament for the prevention or treatment of solid tumour(s).

54. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in the prevention or treatment of tumour types that are sensitive to inhibition and/or degradation of BRD4.

55. Use of a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for the manufacture of a medicament for the prevention or treatment of those tumour types that are sensitive to inhibition and/or degradation of BRD4.

56. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in providing an inhibitory and/or degrading effect on BRD4.

57. Use of a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for the manufacture of a medicament for providing an inhibitory and/or degrading effect on BRD4.

58. The compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for use in providing a selective inhibitory and/degrading effect on BRD4.

59. Use of a compound of **Formula (I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 or 10-18, for the manufacture of a medicament for providing a selective inhibitory and/or degrading effect on BRD4.